Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Manipulation of the activity of the p53 tumor suppressor pathway has demonstrated potential benefit in preclinical mouse tumor models and has entered human clinical trials. We describe here an improved, extensive small-molecule chemical compound library screen for p53 pathway activation in a human cancer cell line devised to identify hits with potent antitumor activity. We uncover six novel small-molecule lead compounds, which activate p53 and repress the growth of human cancer cells. Two tested compounds suppress in vivo tumor growth in an orthotopic mouse model of human B-cell lymphoma. All compounds interact with DNA, and two activate p53 pathway in a DNA damage signaling-dependent manner. A further screen of a drug library of approved drugs for medicinal uses and analysis of gene-expression signatures of the novel compounds revealed similarities to known DNA intercalating and topoisomerase interfering agents and unexpected connectivities to known drugs without previously demonstrated anticancer activities. These included several neuroleptics, glycosides, antihistamines and adrenoreceptor antagonists. This unbiased screen pinpoints interference with the DNA topology as the predominant mean of pharmacological activation of the p53 pathway and identifies potential novel antitumor agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“Z-factor [22] for the screen was 0.632.”
InfluentialLamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“Pilot studies using Hdm2 inhibitory compounds show remarkable in vivo anti-tumor effects without side effects [13,17,19,20].”
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 3×
“As p53 is highly sensitive to DNA damage [2,32] and as DNA intercalators may cause DNA damage, we assessed whether the compounds cause activation of the DNA damage signaling pathways.”
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 1×
“To further assess the regulation of known p53 target genes by the lead compounds we undertook qPCR analysis of eleven known p53 targets. In order to validate p53 dependency, a comparison between the responses in isogenic HCT116 p53+/+ and p53−/− cell lines”
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985 · cited 2×
“This consisted of generation of a cell line expressing red-emitting fluorescent protein under the control of a p53 consensus promoter (p53DsRed) [21].”
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286 · cited 2×
“During tumor evolution, the p53 gene, TP53 , is frequently mutated, yet, over 50% of human tumors harbor the wild type gene [3,4].”
Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141 · cited 1×
“p53, when activated, exerts an extensive transcriptional program affecting hundreds of target genes [34,35].”
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 5×
“Encouragingly, several of the compounds activate p53 without launching a cellular DNA damage response ( i.e. do not impose genotoxic effects on the normal tissues), indicating that they employ activation of events other than DNA damage [19].”
InfluentialShangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · cited 1×
“Pilot studies using Hdm2 inhibitory compounds show remarkable in vivo anti-tumor effects without side effects [13,17,19,20].”
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 1×
“. More recent, switchable p53 expression models in mouse demonstrate that activation of p53 expression leads to regression of several tumor types by invoking apoptosis, senescence and the cellular innate immunity”
Cancer risk among users of neuroleptic medication: a population-based cohort study
Dalton, S. O., Johansen, C., Poulsen, A. H., Nørgaard, M., Sørensen, H. T., McLaughlin, J. K., Mortensen, P. B., & Friis, S. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603259 · Cited by 123 · cited 1×
“Interestingly, a large population-based cohort study of the use of phenothiazines has indicated a decrease in risk of rectal, colon and prostate cancer [44].”
Cited by
mTORC1 Controls Phase Separation and the Biophysical Properties of the Cytoplasm by Tuning Crowding
Delarue, M., Brittingham, G. P., Pfeffer, S., Surovtsev, I. V., Pinglay, S., Kennedy, K. J., Schaffer, M., Gutierrez, J. I., Sang, D., Poterewicz, G., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.042 · Cited by 535
A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity
Peltonen, K., Colis, L., Liu, H., Trivedi, R., Moubarek, M. S., Moore, H. M., Bai, B., Rudek, M. A., Bieberich, C. J., & Laiho, M. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.009 · Cited by 314
Self-citationRibosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance
Elhamamsy, A. R., Metge, B. J., Alsheikh, H. A., Shevde, L. A., & Samant, R. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4087 · Cited by 300
The Ribosome Biogenesis—Cancer Connection
Penzo, M., Montanaro, L., Treré, D., & Derenzini, M. (2019) · Cells · doi:10.3390/cells8010055 · Cited by 242
“Unlike CX-5461 it lacks the common intercalator property of causing DNA damage [61].”
BackgroundImpaired ribosome biogenesis: mechanisms and relevance to cancer and aging
Turi, Z., Lacey, M., Mistrik, M., & Moudry, P. (2019) · Aging · doi:10.18632/aging.101922 · Cited by 215
“Besides its incorporation into the rDNA, BMH-21 also promotes the proteasomal degradation of Pol I [109, 110].”
Background
Metadata
- Authors
- Peltonen, K., Colis, L., Liu, H., Jäämaa, S., Moore, H. M., Enbäck, J., Laakkonen, P., Vaahtokari, A., Jones, R. J., af Hällström, T. M., & Laiho, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-09-27
- Volume
- 5
- Issue
- 9
- Pages
- e12996
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2069543945
- Cited by
- 99
- References
- 18
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.